Treatment Advances

Our Treatment Advances articles cover treatment option updates, new combinations of treatments, FDA approval news, and more.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Predicta Biosciences Raises $5.2M to Improve Myeloma Testing and Monitoring

July 18, 2024

The emerging precision oncology company plans to drastically improve multiple myeloma testing and monitoring through cutting-edge technology and science.

Real-World CAR T Data for Extramedullary Patients

July 17, 2024

Extramedullary myeloma patients need durable, deep-response-inducing treatment. Could CAR T-cell therapy be the answer?

Smoldering Myeloma: What We Know And Where We’re Going

July 16, 2024

New research and clincial trial for high risk smoldering myeloma

CHIP and Multiple Myeloma: Impact on Stem Cell Transplant & Survival Rates

May 08, 2024

Learn how CHIP gene mutations impact patients undergoing a stem cell transplant. Explore survival rates, treatment options, and the role of IMiDs.

Can AI Detect MGUS Progression With Our Fat Cells?

April 30, 2024

Get to know early signs of multiple myeloma progression with AI-driven bone marrow adipocyte analysis. Explore groundbreaking research.

MRD as a Clinical Trial Endpoint: A Patient Perspective

April 22, 2024

Learn why patients believe MRD is useful as and early clinical trial endpoint in multiple myeloma

Positive Vote by FDA ODAC Committee to use MRD as Earlier Myeloma Clinical Trial Endpoint

April 15, 2024

The FDA ODAC Committee makes a historic 12-0 vote to approve Minimal Residual Disease (MRD) as a new clinical trial endpoint in multiple myeloma.

New Target for Relapsed Myeloma: LILRB4-directed CAR-T Therapy

April 12, 2024

New research suggests that targeting LILRB4 may be effective for relapsed myeloma. Learn more about CAR-T, LILRB4, and potential benefits for patients.